NephroGenex aims to sell 2,365,930 shares through its public offering

Bookrunner Aegis helps fund clinical development and working capital

By Devika Patel

Knoxville, Tenn., July 7 – NephroGenex, Inc. plans to sell 2,365,930 shares with warrants for 2,365,930 shares in its public sale with a 45-day greenshoe of 354,889 additional shares and 354,889 additional warrants, according to an S-1/A filed Tuesday with the Securities and Exchange Commission. The company has registered up to $38,812,495 of stock for the sale, which was announced April 20.

Aegis Capital Corp. is the bookrunner.

Proceeds will be used for working capital and general corporate purposes.

The Raleigh, N.C., pharmaceutical company develops therapeutics to treat kidney disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.